Alcobra pulls plug on ADHD drug after PhIII failure
Alcobra’s experimental therapy for the treatment of attention-deficit hyperactivity disorder in adults has failed to hit targets in a late-stage trial, throwing a shadow of doubt over the future of the company.
Read More
